KDR and nasopharyngeal carcinoma: A randomized phase 2 study is also assessing nivolumab plus ipilimumab, with or without the VEGFR2 inhibitor cabozantinib, in NPC patients with disease progression after gemcitabine-cisplatin plus a PD-1 inhibitor (NCT05904080).